Subcutaneous Heparin in the Treatment of Interstitial Cystitis

Lose, Gunnar; Jespersen, Jørgen; Frandsen, Bent; Højensgård, Jens C.; Astrup, Tage

doi:10.3109/00365598509180218

Cited by 33 publications

(4 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In the bladder, there is little heparin is absorbed systemically, even in the inflamed bladder . Although uncontrolled studies have shown that subcutaneous heparin administration has some beneficial effects, the apparent risks of anticoagulation and osteoporosis have prevented this form of administration from further testing and general use. Currently, there is no agreement on the duration, frequency, or dose of intravesical heparin therapy.…”

Section: Current Intravesical Therapy For Ic/bpsmentioning

confidence: 99%

Advances in intravesical therapy for bladder pain syndrome (BPS)/interstitial cystitis (IC)

Meng

Hsu

Chuang

2018

LUTS

View full text Add to dashboard Cite

Bladder pain syndrome (BPS)/interstitial cystitis (IC) is a chronic symptom complex that may cause bothersome storage symptoms and pain or discomfort of the bladder, adversely affecting a patient's quality of life. The etiology of IC/BPS remains unclear, and its cause may be multifactorial. Diagnosis of IC/BPS is based on clinical features, and the possibility of other conditions must be ruled out first. Although no definitive treatment is currently available for IC/BPS, various intravesical therapies are used for IC/BPS, including heparin, hyaluronic acid, chondroitin sulfate, pentosan polysulfate, dimethylsulfoxide, liposomes, and botulinum onabotulinumtoxinA (BoNT-A). This review summarizes the intravesical therapy for IC/BPS and discusses recent advances in the instillation of liposomal-mediated BoNT-A and other newly developed intravesical therapies.

show abstract

Section: Current Intravesical Therapy For Ic/bpsmentioning

confidence: 99%

Advances in intravesical therapy for bladder pain syndrome (BPS)/interstitial cystitis (IC)

Meng

Hsu

Chuang

2018

LUTS

View full text Add to dashboard Cite

show abstract

“…However, heparins also have anti-inflammatory properties. Within ophthalmology, the use of heparin-coated lenses has reduced inflammatory complications after cataract surgery [7], and in chronic interstitial cystitis normalization of the bladder mucosa and reduction of pain scores after heparin treatment have been reported [8, 9]. No studies to date have investigated the anti-inflammatory properties of heparin in patients with ESRD, including patients on peritoneal dialysis (PD).…”

Section: Introductionmentioning

confidence: 99%

Intraperitoneal Heparin Ameliorates the Systemic Inflammatory Response in PD Patients

Sjøland¹,

Pedersen²,

Jespersen³

et al. 2005

Nephron Clin Pract

Self Cite

View full text Add to dashboard Cite

Background: Patients with end-stage renal disease (ESRD) suffer from high mortality rates of cardiovascular diseases, conditions closely linked to the magnitude of their chronic low-grade inflammation. As heparins have been suggested to possess anti-inflammatory properties, we set out to investigate the impact of long-term treatment with intraperitoneal heparin on local and systemic inflammation in peritoneal dialysis (PD) patients. Methods: In a double-blinded cross-over study, 21 PD patients with ESRD were randomised to inject either 4,500 anti-Xa IU tinzaparin or placebo (isotonic saline) into their morning dialysis bags every day for two periods of 3 months separated by a 1-month wash-out period. Blood and dialysate samples were analysed for inflammatory markers at the start and end of each treatment period. In dialysate, the appearance rates of the inflammatory markers were calculated to adjust for ultrafiltration variations. Results: Eleven patients completed the trial. Treatment with intraperitoneal tinzaparin was accompanied with a median 25.8% reduction of the plasma C-reactive protein concentration (p = 0.032), a 7.3% reduction of the plasma fibrinogen concentration (p = 0.042) and a 54.5% reduction of the dialysate interleukin 6 appearance rate (p = 0.007) compared with placebo. Conclusion: Long-term treatment with intraperitoneal tinzaparin of ESRD patients on PD reduces local and systemic concentrations of inflammatory markers.

show abstract

“…Recently, we have found that subcutaneous heparin treatment may relieve symptoms in patients with IC [2,20], Since heparin reacts with ECP [3], the effects of ECP on coagulation and fibrinolysis may be neutralized and consequently the activation of complement decreased. Furthermore, as heparin reacts with both AIF and cell surface receptors it is suggested that the observed clinical effect is due also to a normalization of the composition of GAGs with respect to affinities to cell surface recep tors leading to restoration of a disturbed barrier function of the bladder wall.…”

Section: Discussionmentioning

confidence: 99%

Autorosette Inhibition Factor: A Positive Acute Phase Reactant in Interstitial Cystitis

Frandsen¹,

Lose²,

Holm-Bentzen³

1988

Eur Urol

View full text Add to dashboard Cite

Subcutaneous Heparin in the Treatment of Interstitial Cystitis

Cited by 33 publications

References 11 publications

Advances in intravesical therapy for bladder pain syndrome (BPS)/interstitial cystitis (IC)

Advances in intravesical therapy for bladder pain syndrome (BPS)/interstitial cystitis (IC)

Intraperitoneal Heparin Ameliorates the Systemic Inflammatory Response in PD Patients

Autorosette Inhibition Factor: A Positive Acute Phase Reactant in Interstitial Cystitis

Contact Info

Product

Resources

About